The Bio-Capitalist Edge

We dismantle biotechnology PR illusions with science, regulation, and predatory capital. We don't read press releases; we write clinical and financial autopsies

[The Bio-Capitalist Edge @BioCapitalEdge]

99% of biotech media consists of PR agency illusions and mediocre retail investors funding them.

We don’t read press releases. We write clinical and financial autopsies.

Welcome to the War Room of those who dissect science with a scalpel and slaughter the market with capital.👇

[The Bio-Capitalist Edge @BioCapitalEdge]

@EliLillyandCo $LLY ’s “victory” for Jaypirca came at a price: 8% of patients died from fatal infections.

This isn’t a cure. It’s a brutal trade-off. They are celebrating PFS data while the Overall Survival data is conveniently “not mature.”
https://t.co/5T6sgE43dK

#Biotech #Investing

[The Bio-Capitalist Edge @BioCapitalEdge]

$LLY ’s “victory” for Jaypirca came at a price: 8% of patients died from fatal infections.

This isn’t a cure. It’s a brutal trade-off. They are celebrating PFS data while the Overall Survival data is conveniently “not mature.”

https://t.co/5T6sgE43dK

#Biotech #Investing

[The Bio-Capitalist Edge @BioCapitalEdge]

The stock chart is not showing a dip. It is showing the market pricing in a defeat.

#TheBioCapitalistEdge #Investing #Biotech #Stocks $NVO $LLY

[The Bio-Capitalist Edge @BioCapitalEdge]

He asks if it’s undervalued. He is asking the wrong question. This isn’t a debate, it’s an autopsy.

The market is a forward-looking machine. It has already priced in $NVO’s surrender to $LLY.

[StockChaser @StockChaser_]

$NVO hadone of the strongest obesity-drug launches ever

We saw:
• 18,410 scripts in the first full week
• 38,220 by week five
• 600k+ prescriptions by April 1

And yet the stock is now back below the Wegovy pill launch

Why?

• 2026 sales + profit were guided down 5%–13% vs 3% expected
• Competition got tougher fast, with $LLY's Zepbound already entrenched and their FDA approval for a new obesity pill Foundayo
• Their next-generation pipeline results (CagriSema) underperformed relative to Lilly’s tirzepatide

The debate is simple:
Trading at 10.4x P/E, is it undervalued or is the market correctly pricing in a weaker next chapter?

[The Bio-Capitalist Edge @BioCapitalEdge]

This Isn’t Competition, It’s Extinction: Lilly achieved technological supremacy. CagriSema underperformed. The innovation gap is widening.

[The Bio-Capitalist Edge @BioCapitalEdge]

The P/E Ratio is a Trap: A low P/E isn’t a bargain. It’s the market’s consensus that the “E” (Earnings) is going to collapse under competitive pressure.

[The Bio-Capitalist Edge @BioCapitalEdge]

Scripts are a Rearview Mirror: Past prescriptions are irrelevant. The market is pricing the outcome of the future pipeline war, which Lilly is winning.

[The Bio-Capitalist Edge @BioCapitalEdge]

“Scientific courage” is the new PR spin for burning billions in shareholder cash.

Launching 5 Phase 3 trials on flimsy data isn’t a strategy; it’s a gamble with a catastrophic burn rate.

#Biotech #Investing $GSK

https://t.co/fXsSuWAiYF

[The Bio-Capitalist Edge @BioCapitalEdge]

@PersimmonTI $NVO $LLY $xbi

The Oral Pill Paradox: How Convenience Creates Carnage and a New Bloodbath

https://t.co/DWfhwZ2QNI

[The Bio-Capitalist Edge @BioCapitalEdge]

@danielnewmanUV They are a single photograph of the Great Rotation: a mass exodus of capital from the world of Atoms to the world of Bits.

[The Bio-Capitalist Edge @BioCapitalEdge]

@JCanNuSH This isn’t a warning. It is the suicide note of a business model.

We called this weeks ago: The entire “growth story” for companies like $HIMS is built on a legal gray area they prayed the FDA would ignore.

That prayer went unanswered today.

[The Bio-Capitalist Edge @BioCapitalEdge]

@tdkcznsky Speed of Information: The superiority of the automobile spread by word-of-mouth. Today, Eli Lilly’s “small molecule” data hits the entire global market instantly, repricing every old model overnight.

[The Bio-Capitalist Edge @BioCapitalEdge]

A new CEO isn’t a solution, it’s a liability. Their salary & bonus just accelerate the burn rate. The runway to zero just got shorter. https://t.co/jGkwHorUaz

#Biotech #Investing #Stocks

[The Bio-Capitalist Edge @BioCapitalEdge]

@DrMakaryFDA These unregulated pills contain an unknown dose of a potentially impure and ineffective substance.

This ad doesn’t just represent a company. It represents the end of an era.

The market is a lagging indicator. The law is not.

[The Bio-Capitalist Edge @BioCapitalEdge]

@DrMakaryFDA This isn’t a warning. It is the suicide note of a business model.

We called this weeks ago: The entire “growth story” for companies like $HIMS is built on a legal gray area they prayed the FDA would ignore.

That prayer went unanswered today.

[The Bio-Capitalist Edge @BioCapitalEdge]

@DrMakaryFDA The Regulatory Guillotine: The FDA isn’t “seeing”; it is “targeting.” This is a declaration of war. Warning letters and cease-and-desist orders are coming.

The Scientific Fraud: “Oral Semaglutide” is a biophysical joke. The oral bioavailability of a peptide is less than 1%.

[The Bio-Capitalist Edge @BioCapitalEdge]

@tdkcznsky The world’s finest family-owned horse-drawn carriage company was also very profitable.

Right up until the automobile was invented.

We are not betting on those polishing the carriage. We are betting on those building the engine.

[The Bio-Capitalist Edge @BioCapitalEdge]

$GILD didn’t buy a drug from Kymera. They paid $45M for a press release.

A preclinical story to distract Wall Street from their $12B M&A hangover. This isn’t R&D; it’s narrative management.

#Biotech #Investing #Stocks $GILD

https://t.co/2dyjw5L1AK

[The Bio-Capitalist Edge @BioCapitalEdge]

The FDA rejection isn’t the end. It’s the starting pistol.

The real trade begins now:

Short the $REPL carcass to zero.
Seize the IP in bankruptcy.
Flip it to the original partner, $BMY.
#ShortSelling #Biotech #Investing

https://t.co/9vWpItVv6o

[The Bio-Capitalist Edge @BioCapitalEdge]

@tdkcznsky The real play is not to bet on the current, flawed supply chain.

The real play is to invest in the technology (small molecules, RNA therapies) that will make that entire supply chain prehistoric.

We are betting on the asteroid that makes the gold rush irrelevant.

[The Bio-Capitalist Edge @BioCapitalEdge]

@tdkcznsky He sees one layer deeper: focusing on the supplier, not the consumer brand. But he stops there. And that’s where the trap begins.

The supplier ($BANB) is not the backbone; it is the bottleneck. And bottlenecks are destroyed in two ways:

[The Bio-Capitalist Edge @BioCapitalEdge]

@tdkcznsky The Biophysical Ceiling: Peptide synthesis is a chemical nightmare. It is nearly impossible to scale efficiently. This is why $LLY is pouring billions into a cheap, small-molecule pill (Orforglipron) that makes peptides obsolete.